Your session is about to expire
← Back to Search
fezolinetant for Hot Flashes (Daylight Trial)
Daylight Trial Summary
This trial is for menopausal women with moderate to severe hot flashes who are unable to use hormone replacement therapy. The study will compare the effects of fezolinetant with placebo to see if fezolinetant reduces the number and severity of hot flashes.
- Hot Flashes
Daylight Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDaylight Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 3 trial • 1831 Patients • NCT04003389Daylight Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the maximum number of people who can enroll in this clinical trial?
"That is correct. The information available on clinicaltrials.gov reveals that this trial is searching for patients as we speak. The trial was first advertised on October 25th, 2021 and has since been updated on October 8th, 2020. In total, the study needs 440 individuals from 2 different locations."
Is this clinical trial available to people who are over the age of 65 years old?
"The minimum age that patients can be to enroll in this clinical trial is 40 and the maximum age is 65."
Has fezolinetant undergone FDA approval process yet?
"Fezolinetant's safety is well-documented in prior studies, thus it received a score of 3."
What is the previous research in this field that this study builds off of?
"Development of fezolinetant began in 2021 with the first clinical study being sponsored by Astellas Pharma Global Development, Inc. After the first study, which involved 440 participants, Phase 3 drug approval was granted. As of now, there are 2 active clinical trials involving fezolinetant taking place in 51 cities across 17 countries."
What does the existing research tell us about fezolinetant?
"The first clinical trials for fezolinetant were completed in 2021 at Site DK45002. As of now, there have been 2693 completed trials. Right now, there are 2 ongoing trials; both are based in Montreal, Quebec."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger